Amarin (AMRN) Is 'In Play'
Tweet
Share
E-mail
Get Alerts AMRN Hot Sheet
Join SI Premium – FREE
Shares of Amarin Corporation plc (Nasdaq: AMRN) are higher early Friday as traders get the memo that the stock is "in play," on likely Vascepa NCE approval and then a potential buyout.
Reports after the close Thursday suggested that NCE approval is 'in the bag.' If this is true, attention will turn to the product launch. The company could go it alone, partner with someone, or sell the entire operation.
Recently, analysts at MKM's Partners have been clamoring that a buyout is likely and could come before the end of the year. They said AstraZeneca (NYSE: AZN) is the most logical suitor, but Pfizer, Bristol Myers, Sanofi and others could also be interested.
Shares of AMRN are up 5 percent today to $12.85.
Reports after the close Thursday suggested that NCE approval is 'in the bag.' If this is true, attention will turn to the product launch. The company could go it alone, partner with someone, or sell the entire operation.
Recently, analysts at MKM's Partners have been clamoring that a buyout is likely and could come before the end of the year. They said AstraZeneca (NYSE: AZN) is the most logical suitor, but Pfizer, Bristol Myers, Sanofi and others could also be interested.
Shares of AMRN are up 5 percent today to $12.85.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NS
- Dollar Tree (DLTR) falls 5.6% after Director filed notice to sell $133.1M worth of shares
Create E-mail Alert Related Categories
Insiders' Blog, Momentum Movers, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
